Chase Sun Pharmaceutical released its 2026 interim report. Total operating revenue was 2.188 billion yuan, down 21.72% from the same period last year. Net profit attributable to the parent company was 78.0889 million yuan, down 0.69% year-on-year. Net cash inflow from operating activities was 358 million yuan, down 6.63% year-on-year. The company's asset-liability ratio was 15.93%, gross margin was 56.99%, ROE was 0.91%, and diluted earnings per share was 0.03 yuan. The number of shareholders was 86,300, and the top ten shareholders held 43.32% of the total share capital.
Tianjin Chase Sun Pharmaceutical Co LtdInterim net profit fell 0.69% and revenue dropped 21.72% year-on-year.
